```
     FILE 'REGISTRY' ENTERED AT 16:54:50 ON 31 JUL 2007
L1              STRUCTURE UPLOADED
L2           50 S L1 SSS SAM
L3         4232 S L1 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 16:55:38 ON 31 JUL 2007
L4         1759 S L3
L5        11686 S ?CALCEM?
L6           12 S L4 AND L5
L7       116530 S ?THYROID?
L8          104 S L7 AND L4
L9           94 S L8 NOT L6
L10          37 S L9 AND 1800<=PY<=2002
L11       23600 S PARATHYR?
L12           1 S L11 AND L10

     FILE 'STNGUIDE' ENTERED AT 16:57:14 ON 31 JUL 2007

     FILE 'HCAPLUS' ENTERED AT 17:10:21 ON 31 JUL 2007
              E HYPERCALCEMIA+ALL/CT
L13        5532 S (HYPERCALCEMIA OR "HYPERCALCEMIA")
L14          12 S L13 AND L4
L15           0 S L14 NOT L6
L16          48 S PARATHYROIDISM
              E HYPERPARATHYROIDISM+ALL/CT
L17       41704 S (HYPERPARATHYROIDISM OR "DISEASE, ANIMAL" OR "DISEASES, BY BO
L18          57 S L17 AND L4
L19          54 S L18 NOT L6
L20          52 S L18 NOT L10
L21           5 S L20 AND 1800<=PY<=2002
```

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,N

```
=> s ?thyroid?
L7      116530 ?THYROID?

=> d his

     (FILE 'HOME' ENTERED AT 16:54:45 ON 31 JUL 2007)

     FILE 'REGISTRY' ENTERED AT 16:54:50 ON 31 JUL 2007
L1             STRUCTURE UPLOADED
L2           50 S L1 SSS SAM
L3         4232 S L1 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 16:55:38 ON 31 JUL 2007
L4         1759 S L3
L5        11686 S ?CALCEM?
L6           12 S L4 AND L5
L7       116530 S ?THYROID?

=> s l7 and l4
L8          104 L7 AND L4

=> s l8 not l6
L9           94 L8 NOT L6

=> S L9 AND 1800<=PY<=2002
      22880490 1800<=PY<=2002
L10          37 L9 AND 1800<=PY<=2002

=> s parathyr?
L11      23600 PARATHYR?

=> s l11 and l10
L12           1 L11 AND L10

=> d l12 ibib abs hitstr

L12  ANSWER 1 OF 1  HCAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2005:77981  HCAPLUS
DOCUMENT NUMBER:          142:162662
TITLE:                    Nanoparticulate glipizide compositions
INVENTOR(S):              Bosch, H. William; Ryde, Niels P.
PATENT ASSIGNEE(S):       Elan Pharma International Limited, USA
SOURCE:                   U.S. Pat. Appl. Publ., 24 pp., Cont.-in-part of U.S.
                          Ser. No. 276,400.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   18
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     US 2005019412         A1    20050127    US 2003-701064          20031105
     US 2002012675         A1    20020131    US 1999-337675          19990622 <--
     WO 2001087264         A2    20011122    WO 2001-US15983         20010518 <--
     WO 2001087264         A3    20020620
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
             RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
```

UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2004013613	A1	20040122	US 2003-276400	20030115
PRIORITY APPLN. INFO.:			US 1998-164351	B2 19981001
			US 1999-337675	A2 19990622
			WO 2001-US15983	W 20010518
			US 2003-276400	A2 20030115
			US 2000-572961	A 20000518

AB The present invention is directed to nanoparticulate compns. comprising glipizide. The glipizide particles of the composition preferably have an effective average particle size of <2 μ. Thus, a formulation contained spray-dried glipizide 5.33, mannitol 13.47, xylitol 40.53, citric acid 19.60, sodium bicarbonate 19.33, Asparatme 0.28, PEG-4000 0.93, and sodium stearyl fumarate 0.53%.

IT 79794-75-5, Loratadine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nanoparticulate glipizide compns.)

RN 79794-75-5 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-, ethyl ester (CA INDEX NAME)



=> fil stng

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	76.31	248.62

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-10.14	-10.14

FILE 'STNGUIDE' ENTERED AT 16:57:14 ON 31 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jul 30, 2007 (20070730/UP).

=> d his

(FILE 'HOME' ENTERED AT 16:54:45 ON 31 JUL 2007)

FILE 'REGISTRY' ENTERED AT 16:54:50 ON 31 JUL 2007

```
L1             STRUCTURE UPLOADED
L2            50 S L1 SSS SAM
L3          4232 S L1 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 16:55:38 ON 31 JUL 2007
L4          1759 S L3
L5         11686 S ?CALCEM?
L6            12 S L4 AND L5
L7        116530 S ?THYROID?
L8           104 S L7 AND L4
L9            94 S L8 NOT L6
L10           37 S L9 AND 1800<=PY<=2002
L11        23600 S PARATHYR?
L12            1 S L11 AND L10

     FILE 'STNGUIDE' ENTERED AT 16:57:14 ON 31 JUL 2007
```

L6 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:538752 HCAPLUS
DOCUMENT NUMBER: 146:521817
TITLE: N-Alkyl-N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and their preparation and use in the treatment of diseases
INVENTOR(S): Cai, Sui Xiong; Sirisoma, Nilantha Sudath; Kemnitzer, William E.
PATENT ASSIGNEE(S): Cytovia, Inc, USA
SOURCE: PCT Int. Appl., 59pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007056214	A2	20070518	WO 2006-US43086	20061102

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-732131P P 20051102
OTHER SOURCE(S): MARPAT 146:521817
GI



I



II



III

AB Disclosed are N-alkyl-N-aryl-thienopyrimidin-4-amines and analogs thereof,

represented by the formulas I and II. The invention relates to the discovery that compds. having formulas I and II are activators of caspases and inducers of apoptosis. Compds. of formula I and II wherein Ar is (un)substituted (hetero)aryl; R1 is H, halo, (un)substituted amino, (un)substituted alkoxy, (un)substituted C1-10 alkyl, haloalkyl, (hetero)aryl, etc.; R2, R3 and R4 are independently H, halo, amino, alkoxy, C1-10 alkyl haloalkyl, etc.; R10 are (un)substituted alkyl; and their pharmaceutically acceptable salts, prodrugs and tautomers thereof, are claimed. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clin. conditions in which uncontrolled growth and spread of abnormal cells occurs. Example compound III was prepared by cyclization of 3-aminothiophene-2-carboxylic acid Me ester with acetonitrile; the resulting 2-methylthieno[3,2-d]pyrimidin-4-ol underwent chlorination to give 4-chloro-2-methylthieno[3,2-d]pyrimidine, which underwent amination with N-methyl-p-anisidine to give compound III. All the invention compds. were evaluated for their caspase cascade activity towards various cancer cell lines. From the assay, it was determined that compound IiI exhibited EC50 values of 14 nM against T-47D, 24 nM against H1299, and 28 nM against SNU398.

IT 193275-84-2, SCH66336
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug; preparation of N-alkyl-N-arylthienopyrimidinamine compds. as activators of caspases and apoptosis inducers useful in treatment of diseases)

RN 193275-84-2 HCAPLUS

CN 1-Piperidinecarboxamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L6 ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:484377 HCAPLUS
DOCUMENT NUMBER: 146:482086
TITLE: Preparation of N-arylalkyl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis
INVENTOR(S): Cai, Sui Xiong; Drewe, John A.; Kemnitzer, William E.; Sirisoma, Nilantha Sudath
PATENT ASSIGNEE(S): Cytovia, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 23pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007099941	A1	20070503	US 2006-591531	20061102
WO 2007056208	A2	20070518	WO 2006-US43080	20061102

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-732139P P 20051102
OTHER SOURCE(S): MARPAT 146:482086
GI



I



II

AB Disclosed are N-arylalkyl-thienopyrimidin-4-amines and analogs thereof, represented by the formula I [wherein Ar =(un)substituted (hetero)aryl; R1 = H, halo, (un)substituted amino, etc.; R3, R4 = independently H, halo, alkyl, etc.; R10 = H or (un)substituted alkyl; R11, R12 = independently H or (un)substituted alkyl; n = 1-3; and pharmaceutically acceptable salts prodrugs or tautomers thereof] were prepared as activators of caspases and inducers of apoptosis. For example, reaction of 4-chlorothieno[3,2-d]pyrimidine with 3,4-methylenedioxybenzylamine gave II in 43% yield. I were identified as Caspase Cascade activators and inducers of Apoptosis in human breast cancer cell line T-47D and human lung cancer cell line H1299, and as antineoplastic agents. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clin. conditions in which uncontrolled growth and spread of abnormal cells occurs.

IT 193275-84-2, SCH66336
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug; preparation of N-arylalkyl-thieno[3,2-d]pyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis)

RN 193275-84-2 HCAPLUS

CN 1-Piperidinecarboxamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)



L6 ANSWER 3 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:484293 HCAPLUS
DOCUMENT NUMBER: 146:482085
TITLE: Preparation of N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis
INVENTOR(S): Cai, Sui Xiong; Kemnitzer, William E.; Sirisoma, Nilantha Sudath; Zhang, Han-Zhong
PATENT ASSIGNEE(S): Cytovia, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 34pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007099877	A1	20070503	US 2006-591532	20061102
WO 2007056215	A2	20070518	WO 2006-US43087	20061102

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-732140P P 20051102
OTHER SOURCE(S): MARPAT 146:482085
GI



I



II

AB Disclosed are N-aryl-thienopyrimidin-4-amines and analogs thereof, represented by the formula I & II [wherein Ar =(un)substituted (hetero)aryl; R1 = H, halo, (un)substituted amino, etc.; R2-R4 = independently H, halo, alkyl, etc.] and pharmaceutically acceptable salts prodrugs or tautomers thereof. For example, reaction of 4-chloro-2-methylthieno[3,2-d]pyrimidine with 2,5-dimethoxyaniline gave N-(2,5-dimethoxyphenyl)-2-methylthieno[3,2-d]pyrimidin-4-amine in 51% yield. I were identified as Caspase Cascade activators and inducers of Apoptosis in human breast cancer cell line T-47D and human lung cancer cell line H1299, and as antineoplastic agents. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clin. conditions in which uncontrolled growth and spread of abnormal cells occurs.

IT 193275-84-2, SCH66336
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug; preparation of N-aryl-thieno[3,2-d]pyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis)

RN 193275-84-2 HCAPLUS

CN 1-Piperidinecarboxamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L6 ANSWER 4 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:366977 HCAPLUS
DOCUMENT NUMBER: 144:412498
TITLE: Preparation of substituted N-aryl-1H-pyrazolo[3,4-b]quinolin-4-amines and analogs as activators of caspases and inducers of apoptosis
INVENTOR(S): Zhang, Han-Zhong; Cai, Sui Xiong; Drewe, John A.
PATENT ASSIGNEE(S): Cytovia, Inc., USA
SOURCE: PCT Int. Appl., 79 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006041900	A2	20060420	WO 2005-US35793	20051006
WO 2006041900	A3	20060713		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005294430	A1	20060420	AU 2005-294430	20051006
EP 1807426	A2	20070718	EP 2005-818244	20051006
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				

PRIORITY APPLN. INFO.: US 2004-616539P P 20041007
WO 2005-US35793 W 20051006

OTHER SOURCE(S): CASREACT 144:412498; MARPAT 144:412498

GI



I

AB The title compds. I [X = O, NR3, S, SO, SO2; Ar = (un)substituted aryl, heteroaryl, carbocyclyl, etc.; Q = CR2, CR12R13; Y = N, CR10R11; Z = NR1, CR8R9; R1, R3 = H, (un)substituted alkyl; R2, R4-R13 = H, halo, aryl, etc.] which are activators of caspases and inducers of apoptosis and therefore can be used to induce cell death in a variety of clin. conditions in which uncontrolled growth and spread of abnormal cells occurs (biol. data given), were prepared E.g., a multi-step synthesis of 1,3-dimethyl-N-[4-(methoxycarbonyl)phenyl]-1H-pyrazolo[3,4-b]quinolin-4-amine, starting from anthranilic acid and 4-methyleneoxetan-2-one, was given. Pharmaceutical composition comprising the compound I alone or in combination with other therapeutic agents are disclosed.

IT 193275-84-2, SCH66336
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of substituted N-aryl-1H-pyrazolo[3,4-b]quinolin-4-amines and analogs as activators of caspases and inducers of apoptosis)

RN 193275-84-2 HCAPLUS

CN 1-Piperidinecarboxamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-

(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L6 ANSWER 5 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:588556 HCAPLUS
DOCUMENT NUMBER: 143:115395
TITLE: Preparation of derivatives of gambogic acid and analogs as activators of caspases and inducers of apoptosis
INVENTOR(S): Cai, Sui Xiong; Jiang, Songchun; Zhang, Han-Zhong
PATENT ASSIGNEE(S): Cytovia, Inc., USA
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005060663	A2	20050707	WO 2004-US42292	20041217
WO 2005060663	A3	20051222		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2007093456	A1	20070426	US 2006-580263		20060525
PRIORITY APPLN. INFO.:			US 2003-530256P	P	20031218
			WO 2004-US42292	W	20041217

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention is directed to novel derivs. of gambogic acid (I)

and analogs thereof. Thus, 2-(Dimethylamino)ethyl gambogate (II) was prepared from I via esterification with ClCH2CH2NMe2·HCl in the presence of KI and Cs2CO4. The present invention also relates to the discovery that novel derivs. of gambogic acid are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clin. conditions in which uncontrolled growth and spread of abnormal cells occurs. The bioactivity of II was determined [caspase cascade activation EC50 = 676 nM vs. T-47D and EC50 = 1041 nM vs. DLD breast cancer cells; cell proliferation inhibition GI50 = 187 nM (vs. T-47D), GI50 = 173 nM (vs. DLD), GI50 = 101 nM (vs. MX-1), GI50 = 180 nM (vs. SW620), GI50 = 184 nM (vs. H1299), GI50 = 440 nM (vs. HEK293T), GI50 = 192 nM (vs. HEK293H)].

IT 193275-84-2, SCH66336
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination chemotherapy co-agent; preparation of derivs. of gambogic acid and analogs as activators of caspases and inducers of apoptosis)

RN 193275-84-2 HCAPLUS

CN 1-Piperidinecarboxamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L6 ANSWER 6 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:409226 HCAPLUS
DOCUMENT NUMBER: 142:441858
TITLE: Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
INVENTOR(S): Whitehouse, Martha J.; Curd, John G.
PATENT ASSIGNEE(S): Novacea, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 34 pp., Cont.-in-part of U.S. Ser. No. 703,140, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2005101576	A1	20050512	US 2004-841820		20040510
US 2007027120	A1	20070201	US 2006-516776		20060907
PRIORITY APPLN. INFO.:			US 2003-703140	B2	20031106
			US 2002-424546P	P	20021106

US 2004-841820 A1 20040510

AB Methods of treating MDS, or ameliorating a symptom thereof, are disclosed. Specific methods encompass the administration of one or more vitamin D compds., or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with one or more addnl. active agents. Other methods include intermittent administration of a high dose of one or more vitamin D compds., or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with one or more addnl. active agents. Such intermittent administration allows high doses of the vitamin D compds. to be administered while minimizing or eliminating hypercalcemia. Patients having low risk MDS and refractory anemia unresponsive to erythropoietin were entered into a Phase 2 trial to evaluate the effect of high dose pulse administration of calcitriol. Patients were administered weekly oral calcitriol at a dose of 45 μg for 20 consecutive weeks. The calcitriol was formulated in a composition containing the following excipients with the amount given in approx. percentage by weight: 65 % MIGLYol 812N, 30 % GELUCIRE 44/14, 5 % vitamin-E TPGS and about 0.05 % each of butylated hydroxytoluene (BHT) and butylated hydroxyanisole (BHA). The high dose pulse administration of calcitriol showed beneficial effect for the treatment of MDS.

IT 193275-84-2, SARASAR
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as addnl. active agent; vitamin D compds. in treatment of myelodysplastic syndromes)

RN 193275-84-2 HCAPLUS

CN 1-Piperidinecarboxamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L6 ANSWER 7 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:369221 HCAPLUS

DOCUMENT NUMBER: 142:430024

TITLE: Preparation of substituted 2-arylmethylene-N-aryl-N'-aryl-malonamides and analogs as activators of caspases and inducers of apoptosis

INVENTOR(S): Cai, Sui Xiong; Pervin, Azra; Kasibhatla, Shailaja; Nguyen, Bao Ngoc

PATENT ASSIGNEE(S): Cytovia, Inc., USA

SOURCE: PCT Int. Appl., 140 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005037196	A2	20050428	WO 2004-US32570	20041005
WO 2005037196	A3	20051013		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2007043076	A1	20070222	US 2006-572910	20060321

PRIORITY APPLN. INFO.: US 2003-508290P P 20031006
WO 2004-US32570 W 20041005

OTHER SOURCE(S): MARPAT 142:430024
GI



I



II

AB Substituted 2-arylmethylene-N-aryl-N'-aryl-malonamides and analogs I [wherein Ar1, Ar2, Ar3 = independently (un)substituted hetero/aryl, hetero/arylalkyl, (partially) saturated carbocyclic, heterocyclic] were prepared as activators of caspases and inducers of apoptosis for treating neoplasm. For example, II was prepared by acylation of with 3-aminobenzotrifluoride malonyl dichloride and reaction of the diamide with 4-isopropylbenzaldehyde. II exhibited caspase activation (EC50 = 15 nM for human breast cancer cell line T-47D), inhibition of cell proliferation (GI50 = 180 nM for T-47D). II induced apoptosis in Jurkat and T-47D

cells. I can be used to induce cell death in a variety of clin. conditions in which uncontrolled growth and spread of abnormal cells occurs.

IT 193275-84-2, SCH 66336
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy; preparation of 2-arylmethylene-N,N'-diarylmalonamides and analogs as activators of caspases and inducers of apoptosis)

RN 193275-84-2 HCAPLUS

CN 1-Piperidinecarboxamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L6 ANSWER 8 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:565086 HCAPLUS
DOCUMENT NUMBER: 141:123632
TITLE: Preparation of 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis
INVENTOR(S): Cai, Sui Xiong; Zhang, Han-zhong; Kuemmerle, Jared D.; Zhang, Hong; Kemnitzer, William E.
PATENT ASSIGNEE(S): Cytovia, Inc., USA
SOURCE: PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058253	A1	20040715	WO 2003-US40308	20031218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004127521	A1	20040701	US 2003-737865	20031218
US 7144876	B2	20061205		

CA 2509224	A1	20040715	CA 2003-2509224	20031218
AU 2003303373	A1	20040722	AU 2003-303373	20031218
EP 1581213	A1	20051005	EP 2003-808469	20031218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1756547	A	20060405	CN 2003-80106440	20031218
JP 2006516250	T	20060629	JP 2004-563731	20031218
US 2007112003	A1	20070517	US 2006-593030	20061106
PRIORITY APPLN. INFO.:			US 2002-433953P	P 20021218
			US 2003-737865	A3 20031218
			WO 2003-US40308	W 20031218

OTHER SOURCE(S): MARPAT 141:123632

GI



I



II

AB Title compds. I [R1-3 = H, halo, haloalkyl, aryl, etc.; Q = S, O, amino; A = heterocycle, carbocycle] are prepared For instance, 3-amino-4-chlorobenzamidoxime (preparation given) is reacted with 3-chlorothiophene-2-carbonyl chloride (pyridine, reflux, 50 min) to give II. II and other examples are potent caspase cascade activators and inducers of apoptosis in solid tumor cells, e.g., human breast cancer cell lines T-47D and ZR-75-1.

IT 193275-84-2, SCH66336
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combination pharmaceutical; preparation of 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis)

RN 193275-84-2 HCAPLUS

CN 1-Piperidinecarboxamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L6 ANSWER 9 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:534300 HCAPLUS
DOCUMENT NUMBER: 141:65094
TITLE: Substituted 1-benzoyl-3-cyano-pyrrolo[1,2-a]quinolines and analogs as activators of caspases and inducers of apoptosis
INVENTOR(S): Cai, Sui Xiong; Drewe, John A.; Jiang, Sungchun; Kasibhatla, Shailaja; Kuemmerle, Jared Daniel; Sirisoma, Nilantha Sudath; Zhang, Han-Zhong
PATENT ASSIGNEE(S): Cytovia, Inc., USA
SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004055163	A2	20040701	WO 2003-US39550	20031212
WO 2004055163	A3	20040826		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003300883	A1	20040709	AU 2003-300883	20031212
US 2005014759	A1	20050120	US 2003-733229	20031212
US 7135480	B2	20061114		
EP 1578424	A2	20050928	EP 2003-813401	20031212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: US 2002-432608P P 20021212
WO 2003-US39550 W 20031212

OTHER SOURCE(S): MARPAT 141:65094

AB The invention discloses substituted 1-benzoyl-3-cyanopyrrolo[1,2-a]quinolines and analogs thereof. Compds. of the invention are activators of caspases and inducers of apoptosis. Therefore, the compds. of the invention can be used to induce cell death in a variety of clin. conditions in which uncontrolled growth and spread of abnormal cells occurs. Compound prepn is described.

IT 193275-84-2, SCH66336
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(benzoylcyanopyrroloquinolines and analogs as activators of caspases and inducers of apoptosis)

RN 193275-84-2 HCAPLUS
CN 1-Piperidinecarboxamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L6 ANSWER 10 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:430694 HCAPLUS
DOCUMENT NUMBER: 140:417950
TITLE: Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
INVENTOR(S): Whitehouse, Martha J.; Curd, John G.
PATENT ASSIGNEE(S): Novacea, Inc., USA
SOURCE: PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004043360	A2	20040527	WO 2003-US35244	20031106
WO 2004043360	A3	20041014		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2505373	A1	20040527	CA 2003-2505373	20031106
AU 2003291294	A1	20040603	AU 2003-291294	20031106
EP 1562606	A2	20050817	EP 2003-768685	20031106
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1732009	A	20060208	CN 2003-80107379	20031106
JP 2006508125	T	20060309	JP 2004-551746	20031106
MX 2005PA04985	A	20050802	MX 2005-PA4985	20050506

PRIORITY APPLN. INFO.:		
US 2002-424546P	P	20021106
WO 2003-US35244	W	20031106

AB Methods of treating myelodysplastic syndrome (MDS), or ameliorating a symptom thereof, are disclosed. Specific methods encompass the administration of one or more vitamin D compds., or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with one or more addnl. active agents. Other methods include intermittent administration of a high dose of one or more vitamin D compds., or a pharmaceutically acceptable salt, solvate,

hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with one or more addnl. active agents. Such intermittent administration allows high doses of the vitamin D compds. to be administered while minimizing or eliminating hypercalcemia.

IT 193275-84-2, Sarasar
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vitamin D compds. in treatment of myelodysplastic syndrome. and use with other agents)

RN 193275-84-2 HCAPLUS

CN 1-Piperidinecarboxamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L6 ANSWER 11 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2004:310969 HCAPLUS
DOCUMENT NUMBER:	140:332505
TITLE:	Use of tricyclic amides for the treatment of disorders of calcium homeostasis
INVENTOR(S):	Evans, Ellen W.; Choy, Wai Nang; Mirro, Elmer J.
PATENT ASSIGNEE(S):	Schering Corporation, USA
SOURCE:	PCT Int. Appl., 62 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004030669	A1	20040415	WO 2003-US30670	20030929
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003272767	A1	20040423	AU 2003-272767	20030929
US 2004082588	A1	20040429	US 2003-673888	20030929

PRIORITY APPLN. INFO.: US 2002-414948P P 20020930
WO 2003-US30670 W 20030929

OTHER SOURCE(S): MARPAT 140:332505

GI



I

AB The invention provides methods for using tricyclic amide compds., e.g. I, to treat disorders of calcium homeostasis. Such disorders include familial benign hypocalciuric hypercalcemia, neonatal severe primary hyperparathyroidism and renal secondary hyperparathyroidism.

IT 193275-70-6 193275-72-8 193275-73-9
193275-75-1 193275-76-2 193275-77-3
193275-78-4 193275-79-5 193275-81-9
193275-82-0 193275-84-2 193275-85-3
193275-86-4 193275-87-5 193275-88-6
193275-89-7 193275-90-0 193275-91-1
193275-92-2 193275-93-3 193275-94-4
193275-95-5 193275-96-6 193275-98-8
193275-99-9 193276-00-5 193276-01-6
193276-02-7 193276-03-8 193276-04-9
193276-05-0 193276-06-1 193276-07-2
193276-08-3 193276-10-7 193276-11-8
193276-12-9 193276-16-3 193276-18-5
193276-24-3 193276-27-6 193276-29-8
193276-30-1 193276-32-3 193276-33-4
193276-73-2 193278-08-9 193278-09-0
193410-28-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tricyclic amides for treatment of disorders of calcium homeostasis)

RN 193275-70-6 HCAPLUS

CN Piperidine, 4-(3,7-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-[(1-oxido-4-pyridinyl)acetyl]- (9CI) (CA INDEX NAME)



RN 193275-72-8 HCAPLUS
CN 1-Piperidinecarboxamide, 4-[2-[4-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-piperidinyl]-2-oxoethyl]-(9CI) (CA INDEX NAME)



RN 193275-73-9 HCAPLUS
CN Piperazine, 1-[(11S)-3,7-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-4-[(1-oxido-4-pyridinyl)acetyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 193275-75-1 HCAPLUS
CN Piperazine, 1-[(11R)-3,7-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-4-[(1-oxido-4-pyridinyl)acetyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 193275-76-2 HCAPLUS
CN Piperazine, 1-(3,7-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-4-[(1-oxido-4-pyridinyl)acetyl]-(9CI) (CA INDEX NAME)



RN 193275-77-3 HCAPLUS
CN 1-Piperidinecarboxamide, 4-[2-[4-[(11S)-3,7-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperazinyl]-2-oxoethyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 193275-78-4 HCAPLUS
CN 1-Piperidinecarboxamide, 4-[2-[4-(3,10-dibromo-8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidinyl]-2-oxoethyl]-(9CI) (CA INDEX NAME)



RN 193275-79-5 HCAPLUS
CN Piperidine, 4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-[(1-oxido-4-pyridinyl)acetyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 193275-81-9 HCAPLUS
CN Piperidine, 4-[(11S)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-[(1-oxido-4-pyridinyl)acetyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 193275-82-0 HCAPLUS
CN Piperidine, 4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-[(1-oxido-4-pyridinyl)acetyl]-(9CI) (CA INDEX NAME)



RN 193275-84-2 HCAPLUS
CN 1-Piperidinecarboxamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 193275-85-3 HCAPLUS
CN 1-Piperidinecarboxamide, 4-[2-[4-[(11S)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 193275-86-4 HCAPLUS
CN 1-Piperidinecarboxamide, 4-[2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-piperidinyl]-2-oxoethyl]-(9CI) (CA INDEX NAME)



RN 193275-87-5 HCAPLUS
CN Piperazine, 1-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-4-[(1-oxido-4-pyridinyl)acetyl]-(9CI) (CA INDEX NAME)



RN 193275-88-6 HCAPLUS
CN Piperazine, 1-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-4-[(1-oxido-4-pyridinyl)acetyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 193275-89-7 HCAPLUS
CN Piperazine, 1-[(11S)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-4-[(1-oxido-4-pyridinyl)acetyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 193275-90-0 HCAPLUS
CN 1-Piperidinecarboxamide, 4-[2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-piperazinyl]-2-oxoethyl]-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 193275-91-1 HCAPLUS
CN 1-Piperidinecarboxamide, 4-[2-[4-[(11S)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperazinyl]-2-oxoethyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 193275-92-2 HCAPLUS
CN 1-Piperidinecarboxamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperazinyl]-2-oxoethyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 193275-93-3 HCAPLUS
CN 1-Piperidinecarboxamide, 4-[2-[4-[(11S)-3,7-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 193275-94-4 HCAPLUS
CN 1-Piperidinecarboxamide, 4-[2-[4-[(11R)-3,7-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 193275-95-5 HCAPLUS
CN 1-Piperidinecarboxamide, 4-[2-[4-(3,7-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 193275-96-6 HCAPLUS
CN Piperidine, 4-[(11R)-3,7-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-[(1-oxido-4-pyridinyl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 193275-98-8 HCAPLUS
CN Piperidine, 4-[(11S)-3,7-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-[(1-oxido-4-pyridinyl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 193275-99-9 HCAPLUS
CN 1-Piperidinecarboxamide, 4-[2-[4-(3,7-dibromo-8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 193276-00-5 HCAPLUS
CN Piperazine, 1-[(11R)-3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-4-[(1-oxido-4-pyridinyl)acetyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 193276-01-6 HCAPLUS
CN Ethanone, 1-[4-[(11S)-3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperazinyl]-2-(1-oxido-4-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 193276-02-7 HCAPLUS
CN 1-Piperidinecarboxamide, 4-[2-[4-[(11R)-3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 193276-03-8 HCAPLUS
CN 1-Piperidinecarboxamide, 4-[2-[4-[(11S)-3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperazinyl]-2-oxoethyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 193276-04-9 HCAPLUS
CN 1-Piperidinecarboxamide, 4-[2-[4-[(11R)-3-bromo-8,10-dichloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 193276-05-0 HCAPLUS
CN Piperazine, 1-[(11R)-3-bromo-8,10-dichloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-4-[(1-oxido-4-pyridinyl)acetyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 193276-06-1 HCAPLUS
CN Piperazine, 1-(3-bromo-10-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-4-[(1-oxido-4-pyridinyl)acetyl]-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 193276-07-2 HCAPLUS
CN Piperazine, 1-(3-bromo-8-chloro-10-fluoro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-4-[(1-oxido-4-pyridinyl)acetyl]- (9CI) (CA INDEX NAME)



RN 193276-08-3 HCAPLUS
CN Piperazine, 1-(3-bromo-10-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-4-[(1-oxido-4-pyridinyl)acetyl]- (9CI) (CA INDEX NAME)



RN 193276-10-7 HCAPLUS
CN 1-Piperidinecarboxamide, 4-[2-[4-(3,7-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-piperazinyl]-2-oxoethyl]-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 193276-11-8 HCAPLUS
CN Piperazine, 1-(3-bromo-8,10-dichloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-4-[(1-oxido-4-pyridinyl)acetyl]-(9CI) (CA INDEX NAME)



RN 193276-12-9 HCAPLUS
CN 1-Piperidinecarboxamide, 4-[2-[4-(3-bromo-8,10-dichloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-piperidinyl]-2-oxoethyl]-(9CI) (CA INDEX NAME)



RN 193276-16-3 HCAPLUS
CN 1-Piperidinecarboxamide, 4-[2-[4-[(11R)-3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 193276-18-5 HCAPLUS
CN 1-Piperidinecarboxamide, 4-[2-[4-[(11S)-3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 193276-24-3 HCAPLUS
CN 1-Piperidinecarboxamide, 4-[2-[4-(3-bromo-8,10-dichloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-piperazinyl]-2-oxoethyl]-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 193276-27-6 HCAPLUS
CN Piperidine, 4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-[(1-oxido-3-pyridinyl)acetyl]-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 193276-29-8 HCAPLUS
CN 1-Piperidinecarboxamide, 4-[2-[4-(3-bromo-10-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-piperidinyl]-2-oxoethyl]-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 193276-30-1 HCAPLUS
CN 1-Piperidinecarboxamide, 4-[2-[4-(3-bromo-10-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-piperazinyl]-2-oxoethyl]-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 193276-32-3 HCAPLUS
CN 1-Piperidinecarboxamide, 4-[2-[4-(8,10-dibromo-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-piperidinyl]-2-oxoethyl]-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 193276-33-4 HCAPLUS
CN 1-Piperidinecarboxamide, 4-[2-oxo-2-[4-(3,8,10-trichloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-piperidinyl]ethyl]-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 193276-73-2 HCAPLUS
CN Piperidine, 4-(3,10-dibromo-8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-[(1-oxido-4-pyridinyl)acetyl]- (9CI) (CA INDEX NAME)



RN 193278-08-9 HCAPLUS
CN Piperidine, 4-(3,7-dibromo-8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-[(1-oxido-4-pyridinyl)acetyl]- (9CI) (CA INDEX NAME)



RN 193278-09-0 HCAPLUS
CN Piperidine, 4-(3-bromo-8,10-dichloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-[(1-oxido-4-pyridinyl)acetyl]-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 193410-28-5 HCAPLUS
CN 1-Piperidinecarboxamide, 4-[2-[4-[(11R)-3,7-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperazinyl]-2-oxoethyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:20448 HCAPLUS
DOCUMENT NUMBER: 140:87676
TITLE: Derivatives of gambogic acid and analogs as activators of caspases and inducers of apoptosis
INVENTOR(S): Tseng, Ben; Sirisoma, Nilantha Sudath; Cai, Sui Xiong; Zhang, Han-Zhong; Kasibhatla, Shailaja; Ollis, Kristin P.; Drewe, John A.
PATENT ASSIGNEE(S): Cytovia, Inc., USA
SOURCE: PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2004002428	A2	20040108	WO 2003-US20668		20030701
WO 2004002428	A3	20050616			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2491698	A1	20040108	CA 2003-2491698		20030701
AU 2003267977	A1	20040119	AU 2003-267977		20030701
US 2004082066	A1	20040429	US 2003-609670		20030701
US 7176234	B2	20070213			
EP 1562598	A2	20050817	EP 2003-748924		20030701
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
CN 1738620	A	20060222	CN 2003-815628		20030701
JP 2006507227	T	20060302	JP 2004-518157		20030701
PRIORITY APPLN. INFO.:			US 2002-392358P	P	20020701
			US 2002-413649P	P	20020926
			WO 2003-US20668	W	20030701

OTHER SOURCE(S): MARPAT 140:87676

AB The invention is directed to derivs. of gambogic acid and analogs thereof. Exemplary gambogic acid derivs. of the present invention include, among others, derivs. substituted in the C10 and C28 positions of gambogic acid. The present invention also relates to the discovery that certain preferred compds. of the invention are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clin. conditions in which uncontrolled growth and spread of abnormal cells occurs.

IT 193275-84-2, SCH66336
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(derivs. of gambogic acid and analogs as activators of caspases and inducers of apoptosis)

RN 193275-84-2 HCAPLUS

CN 1-Piperidinecarboxamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).